Supply of buprenorphine waivered physicians: The influence of state policies
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Buprenorphine, an effective opioid use disorder treatment, can be prescribed only by buprenorphine-waivered physicians. We calculated the number of buprenorphine-waivered physicians/100,000 county residents using 2008–11 Buprenorphine Waiver Notification System data, and used multivariate regression models to predict number of buprenorphine-waivered physicians/100,000 residents in a county as a function of county characteristics, state policies and efforts to promote buprenorphine use. In 2011, 43% of US counties had no buprenorphine-waivered physicians and 7% had 20 or more waivered physicians. Medicaid funding, opioid overdose deaths, and specific state guidance for office-based buprenorphine use were associated with more buprenorphine-waivered physicians, while encouraging methadone programs to promote buprenorphine use had no impact. Our findings provide important empirical information to individuals seeking to identify effective approaches to increase the number of physicians able to prescribe buprenorphine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577 · cited 1×
“…(naltrexone) and opioid agonist (methadone and buprenorphine) medications(Ball & Ross, 1991 ; Fiellin & O’Connor, 2002; Fiellin et al., 2006; Fudala et al., 2003; Johnson et al., 2000; Kakko, Svanborg, Kreek, & Heilig, 2003; Mattick, Kimber, Breen, & Davoli, 2008; National Consensus…”
Effective Medical Treatment of Opiate Addiction
Addiction, N. C. D. P. O. E. M. T. O. O. (1998) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.280.22.1936 · Cited by 577
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub3 · Cited by 501
Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12600-1 · Cited by 466
A guiding framework and approach for implementation research in substance use disorders treatment.
Damschroder, L. J., & Hagedorn, H. J. (2011) · Psychology of Addictive Behaviors · doi:10.1037/a0022284 · Cited by 427 · cited 1×
“…attributes of the clinical setting where the intervention will be implemented and the broader community context in which such clinical settings exist, characteristics of individuals receiving the intervention, and the process of implementing the intervention (Damschroder & Hagedorn, 2011).”
BackgroundSees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark, H. W., Robillard, H., Banys, P., & Hall, S. M. (2000) · JAMA · doi:10.1001/jama.283.10.1303 · Cited by 415 · cited 1×
“…et al., 2003; Johnson et al., 2000; Kakko, Svanborg, Kreek, & Heilig, 2003; Mattick, Kimber, Breen, & Davoli, 2008; National Consensus Development Panel, 1998; National Institute of Drug Abuse, 2006; National Institute of Drug Abuse National Quality Forum, 2005; Sees et al., 2000; Volkow, 2004).”
BackgroundCounseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence
Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O'Connor, P. G., & Schottenfeld, R. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055255 · Cited by 351 · cited 1×
“…with opioid antagonist (naltrexone) and opioid agonist (methadone and buprenorphine) medications(Ball & Ross, 1991 ; Fiellin & O’Connor, 2002; Fiellin et al., 2006; Fudala et al., 2003; Johnson et al., 2000; Kakko, Svanborg, Kreek, & Heilig, 2003; Mattick, Kimber, Breen, & Davoli, 2008;…”
O’Connor, P., Oliveto, A., Shi, J., Triffleman, E., Carroll, K., Kosten, T., Rounsaville, B., Pakes, J., & Schottenfeld, R. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00194-6 · Cited by 174
Office-Based Treatment of Opioid-Dependent Patients
Fiellin, D. A., & O'Connor, P. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp013579 · Cited by 148 · cited 1×
“…treatments are available, with opioid antagonist (naltrexone) and opioid agonist (methadone and buprenorphine) medications(Ball & Ross, 1991 ; Fiellin & O’Connor, 2002; Fiellin et al., 2006; Fudala et al., 2003; Johnson et al., 2000; Kakko, Svanborg, Kreek, & Heilig, 2003; Mattick, Kimber,…”
Sullivan, L. E., Chawarski, M., O’Connor, P. G., Schottenfeld, R. S., & Fiellin, D. A. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.12.008 · Cited by 110
Cited by
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Van Handel, M. M., Rose, C. E., Hallisey, E. J., Kolling, J. L., Zibbell, J. E., Lewis, B., Bohm, M. K., Jones, C. M., Flanagan, B. E., Siddiqi, A.-E.-A., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001098 · Cited by 438
Haffajee, R. L., Lin, L. A., Bohnert, A. S. B., & Goldstick, J. E. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.6373 · Cited by 261
Update on Barriers to Pharmacotherapy for Opioid Use Disorders
Sharma, A., Kelly, S. M., Mitchell, S. G., Gryczynski, J., O’Grady, K. E., & Schwartz, R. P. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0783-9 · Cited by 163
Dick, A. W., Pacula, R. L., Gordon, A. J., Sorbero, M., Burns, R. M., Leslie, D., & Stein, B. D. (2015) · Health Affairs · doi:10.1377/hlthaff.2014.1205 · Cited by 159
Self-citation
Metadata
- Authors
- Stein, B. D., Gordon, A. J., Dick, A. W., Burns, R. M., Pacula, R. L., Farmer, C. M., Leslie, D. L., & Sorbero, M.
- Venue
- Journal of Substance Abuse Treatment
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 48
- Issue
- 1
- Pages
- 104-111
- ISSN
- 0740-5472 (ISSN-L)
- OpenAlex
- W2089332158
- Cited by
- 109
- References
- 11
- FWCI
- 11.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.